JP2014501287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501287A5 JP2014501287A5 JP2013547705A JP2013547705A JP2014501287A5 JP 2014501287 A5 JP2014501287 A5 JP 2014501287A5 JP 2013547705 A JP2013547705 A JP 2013547705A JP 2013547705 A JP2013547705 A JP 2013547705A JP 2014501287 A5 JP2014501287 A5 JP 2014501287A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- oral
- mast cell
- antihistamine
- stabilizing factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002200 mouth mucosa Anatomy 0.000 claims description 6
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 5
- 229960000265 cromoglicic acid Drugs 0.000 claims description 4
- 206010068355 Oral allergy syndrome Diseases 0.000 claims 2
- 239000013566 allergen Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 230000000087 stabilizing effect Effects 0.000 description 20
- 230000001387 anti-histamine Effects 0.000 description 18
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 16
- 239000000739 antihistaminic agent Substances 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 230000007815 allergy Effects 0.000 description 11
- 208000026935 allergic disease Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- -1 [2-hydroxybenzoyl] amino Chemical group 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000013568 food allergen Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 229960004811 pemirolast potassium Drugs 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98172610A | 2010-12-30 | 2010-12-30 | |
| US12/981,726 | 2010-12-30 | ||
| PCT/US2011/068185 WO2012092594A2 (en) | 2010-12-30 | 2011-12-30 | Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501287A JP2014501287A (ja) | 2014-01-20 |
| JP2014501287A5 true JP2014501287A5 (enExample) | 2015-02-26 |
| JP5996553B2 JP5996553B2 (ja) | 2016-09-21 |
Family
ID=46383882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547705A Expired - Fee Related JP5996553B2 (ja) | 2010-12-30 | 2011-12-30 | 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130017247A1 (enExample) |
| EP (1) | EP2658538A2 (enExample) |
| JP (1) | JP5996553B2 (enExample) |
| WO (1) | WO2012092594A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2705244T3 (es) | 2010-06-16 | 2019-03-22 | Inflammatory Response Res Inc | Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común |
| US20140370086A1 (en) * | 2010-12-30 | 2014-12-18 | Ziv Harish | Sublingual immunotherapy with reduced oral itchiness |
| RU2705097C2 (ru) * | 2013-03-13 | 2019-11-05 | Ирр, Инк. | Применение левоцетиризина и монтелукаста при лечении анафилаксии |
| ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
| CN105228700A (zh) | 2013-03-13 | 2016-01-06 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途 |
| EP2968309A4 (en) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
| CN104546731A (zh) * | 2013-10-09 | 2015-04-29 | 重庆安格龙翔医药科技有限公司 | 一种盐酸依匹斯汀颗粒剂及其制备方法 |
| JP2016535793A (ja) * | 2013-11-11 | 2016-11-17 | ジヴ エム．ディー． ハリシュ | 口腔アレルギー症候群の予防および治療のための製剤および方法 |
| WO2015080292A1 (ja) * | 2013-11-29 | 2015-06-04 | 旭化成イーマテリアルズ株式会社 | 高分子電解質膜 |
| JP2017505348A (ja) * | 2014-02-10 | 2017-02-16 | パタラ ファーマ リミテッド ライアビリティ カンパニー | 肺疾患治療のための肥満細胞安定剤 |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
| EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS |
| CN119970625A (zh) * | 2018-01-15 | 2025-05-13 | 西雅图咖米公司 | 半固态抗组胺组合物及其制备和使用方法 |
| CN110567949B (zh) * | 2019-09-10 | 2021-12-14 | 广东天地和实业控股集团有限公司 | 细菌毒素检测方法及应用于该方法的处理仪 |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1997478T3 (da) * | 2001-02-15 | 2013-12-09 | Access Pharma Inc | Flydende formuleringer til forebyggelse og behandling af slimhindesygdomme og -lidelser |
| US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| WO2006045318A2 (en) * | 2004-10-27 | 2006-05-04 | Aarhus Universitet | Diagnosis and treatment of immune-related diseases |
| WO2008153761A1 (en) * | 2007-05-23 | 2008-12-18 | Mastcell Pharmaceuticals, Inc. | Methods |
-
2011
- 2011-12-30 EP EP11854273.7A patent/EP2658538A2/en not_active Withdrawn
- 2011-12-30 JP JP2013547705A patent/JP5996553B2/ja not_active Expired - Fee Related
- 2011-12-30 WO PCT/US2011/068185 patent/WO2012092594A2/en not_active Ceased
-
2012
- 2012-01-17 US US13/352,277 patent/US20130017247A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5996553B2 (ja) | 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 | |
| JP7284241B2 (ja) | 即効性の植物由来医薬化合物及び栄養補給剤 | |
| US20250120939A1 (en) | Fast-acting plant-based medicinal compounds and nutritional supplements | |
| US20090155189A1 (en) | Preparations, Methods and Kits Useful for the Treatment of Cough | |
| US20140335153A1 (en) | Thin film with high load of active ingredient | |
| JP2026004387A (ja) | 改善されたバイオアベイラビリティーを有するハーブ組成物 | |
| CN1376065A (zh) | 稳定性改善的组合物 | |
| JP2010521420A5 (enExample) | ||
| HUP0105021A2 (hu) | Javított hatóanyag-kibocsátású készítmények és eljárás az előállításukra | |
| CA3049226A1 (en) | Medicinal compounds and nutritional supplements | |
| CA3098112A1 (en) | Pharmaceutical formulation | |
| WO2013116798A2 (en) | A method for the treatment and/or prevention of oral allergic symptoms of the lips due to oral contact with a food allergen | |
| HUP0105028A2 (hu) | Javított stabilitású készítmények és eljárás az előállításukra | |
| US20180055938A1 (en) | Medication With Improved Taste And Sensory Experience | |
| US20080095759A1 (en) | Defense and Counter-Defense Compositions and Methods | |
| AR034701A1 (es) | Nuevas composiciones farmaceuticas con accion antidiabetica y proceso para su preparacion | |
| ZA200201892B (en) | Compositions having improved stability. |